We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

2 hedge funds and large institutions have $314K invested in Loncar China BioPharma ETF in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

398% more capital invested

Capital invested by funds: $63K → $314K (+$251K)

0% more funds holding

Funds holding: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$279K

Top Sellers

Rank Fund Capital Flow
1
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$15K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
1
Jane Street
New York
$270K +$279K +12,166 New
Morgan Stanley
2
Morgan Stanley
New York
$44K – – –
PNC Financial Services Group
3
PNC Financial Services Group
Pennsylvania
– -$15K -652 Closed

CHNA Hedge Fund Activity: Q2 2019 in Review

2 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q2 2019, worth a combined $314K — up 398% from $63K a quarter earlier.

Fund positioning in CHNA was balanced in Q2 2019: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $279K. The largest seller was PNC Financial Services Group, exiting entirely with an estimated $15K sold.

  • 2 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $314K of Loncar China BioPharma ETF stock for Q2 2019, up 398% quarter-over-quarter.
  • 1 fund opened new Loncar China BioPharma ETF positions in Q2 2019 and 1 closed out, a net change of 0 holders.
  • The largest Loncar China BioPharma ETF buyer in Q2 2019 was Jane Street, an estimated $279K added.
  • The largest Loncar China BioPharma ETF seller in Q2 2019 was PNC Financial Services Group, an estimated $15K sold.

Based on aggregated 13F filings for Q2 2019.